AJANTPHARMBSEAjanta Pharma LtdHighNegative
Announced Tue, 9 Jun · 10:22 IST

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 08, 2026 for Aayush Agrawal, trustee ....

Pledge Above 50pctOwnership Changes View source PDF

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.6%1-day move
₹2970.00
prior close
₹3027.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.2-0.3-0.1+3.6+5.8+6.1+2.6+4.0+3.9+12.6+11.3
Up moveDown movePending
AI summary

Ajanta Pharma promoter Aayush Agrawal (through Aayush Agrawal Trust) has created a pledge on 28,55,925 shares of the company, which works out to about 2.29% of Ajanta Pharma's total share capital. The pledge was created on 2 June 2026 and the stated reason is to raise a new loan. After this pledge, the trust's holding stands at around 33.48 lakh shares, of which nearly 28.86 lakh (about 86%) are now encumbered, up from just 30,000 shares pledged earlier. The disclosure was filed with BSE and NSE under Regulation 31(1) and 31(2) of SEBI's Substantial Acquisition of Shares and Takeovers (SAST) Regulations, 2011.

Likely market impact

More than 85% of this specific promoter's stake is now pledged, which is a red flag for retail investors as high pledging can indicate leveraged financial positions or stress. The shares themselves have not been sold, so there is no equity dilution, but any future loan default could trigger invocation of the pledged shares and pressure on the stock.